Overview

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has a higher risk of coming back after surgery (high-risk).
Phase:
Phase 1
Details
Lead Sponsor:
Ashley Holder, MD
The Methodist Hospital Research Institute
Collaborator:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab